More Post from the Author
- SIRUI Wins "Best of Show", Unveils New Cine Lenses at NAB Show 2026
- Akemona to Power Upcoming Tokenized Offering for Industrialized Innovation Impact Portfolio I
- La vacunacin materna contra el VRS reduce el riesgo de hospitalizacin infantil en ms del 80%
- ESCMID Global: Maternal RSV vaccination cuts infant hospitalisation risk by over 80%, major UKHSA study finds
- CGTN: Ako kultrne vmeny podporuj nsko-vietnamsk priatestvo
Sekisui Specialty Chemicals Announces Global Price Increase
DALLAS, April 10, 2025 /PRNewswire/ -- Sekisui Specialty Chemicals announced today that it will increase the price of Selvol Polyvinyl Alcohol, Selvol Ultiloc, Selvol Ultalux, and Selvol Premiol products up to the amounts shown in the table.
Region | Increase: |
North America | $200/mt |
Latin America | $200/mt |
Asia | $200/mt |
EMEA | 200EUR/mt |
Sekisui Specialty Chemicals remains committed to meeting customers' needs with high quality products. The increase will take effect on May 15th, 2025, or as contracts and agreements allow. Customers should contact their local Sekisui sales representative for more details.
Sekisui Specialty Chemicals' primary product is Selvol, a line of high-performance polyvinyl alcohol polymers and copolymers used in paper, adhesive, packaging, construction, personal care, and many other specialty formulations. Selvol Ultiloc copolymers are Sekisui's the most recent innovation, bringing new functionality to the long trusted Selvol product line. The company also represents Advancell expandable microspheres and S-LEC BK polyvinyl acetal resins. Sekisui Specialty Chemicals is a subsidiary of the Sekisui Chemical Group, a multibillion dollar, global company that delivers a wide range of products and services to enrich people's lives. The company is comprised of core businesses and technologies in housing, social infrastructure, and chemical solutions. For more information, visit www.sekisui-sc.com/
SOURCE Sekisui Specialty Chemicals

More Post from the Author
- SIRUI Wins "Best of Show", Unveils New Cine Lenses at NAB Show 2026
- Akemona to Power Upcoming Tokenized Offering for Industrialized Innovation Impact Portfolio I
- La vacunacin materna contra el VRS reduce el riesgo de hospitalizacin infantil en ms del 80%
- ESCMID Global: Maternal RSV vaccination cuts infant hospitalisation risk by over 80%, major UKHSA study finds
- CGTN: Ako kultrne vmeny podporuj nsko-vietnamsk priatestvo
